Qiagen : 2023 results above estimates – 2024 guidance looks cautious
>Strong Q4 drives 2023 results above expectations - Thanks to a strong Q4 with sales CER up by 1% to $ 503m, despite a -43% sales decrease in Covid-19 product groups, Qiagen met its FY 2023 sales guidance of € 1.97bn - in contrast to our and the consensus expectations. The group also over-delivered on its CER adj. EPS target of $ 2.07 and achieved $ 2.09, vs our estimates of $ 2.06 and consensus of $ 2.05. The high 2023 revenue growth in non-Covid product groups (CER ...Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.